ADCs are innovative therabees
1. A new class of biopharmaceutical drugs used to treat cancer
2. A more precise anti-tumor targeting
3. A stronger therapeutic effectiveness
4. A better quality of life for patients
With a potent future
4 ADCs launched
85 ADCs in active clinical development
They are composed of 3 elements
mAb (Monoclonal AntiBody): Specific protein that recognizes and targets cancer cells
Payload: Highly active ingredient that kills cancer cells
Linker: Small molecule that connects the cytotoxic payload to the mAb
Do you want to learn more?
